COSENTYX
secukinumab
- Strength
- 75 mg/.5mL
- Form
- Injection
- Class
- Interleukin-17A Antagonist
Novartis Pharmaceuticals Corporation
COSENTYX
secukinumab
Listed by Novartis Pharmaceuticals Corporation
- Strength
- 25 mg/mL
- Form
- Injection, Solution, Concentrate
- Route
- Intravenous
- Class
- Interleukin-17A Antagonist
What it contains
- Secukinumab 25 mg/mL
FDA record
| Dosage form | Injection, Solution, Concentrate |
|---|---|
| Route | Intravenous |
| Drug class | Interleukin-17A Antagonist |
| Approval route | BLA — biologic licence |
| NDC code | 0078-1168 |
| FDA application | BLA761349 |
| RxNorm concept | 1599792 |
| Package sizes listed | 1 |
| Marketed since | October 2023 |
Other products containing Secukinumab
See allSame active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
COSENTYX
secukinumab
- Strength
- 150 mg/mL
- Form
- Injection
- Class
- Interleukin-17A Antagonist
Novartis Pharmaceuticals Corporation
COSENTYX
secukinumab
- Strength
- 300 mg/2mL
- Form
- Injection
- Class
- Interleukin-17A Antagonist
Novartis Pharmaceuticals Corporation
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.